FBRX Stock Analysis: Forte Biosciences | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 428m USD | 12M Return: 75.9% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 5.43M
Qual. Beats: 0
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 9.2 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Forte Biosciences, Inc. (FBRX) is a U.S.-based clinical-stage biopharmaceutical company headquartered in Dallas, Texas. Its lead product candidate, FB-102, is a proprietary anti-CD122 monoclonal antibody being developed for autoimmune and autoimmune-related indications including celiac disease, vitiligo, alopecia areata, and type 1 diabetes.
As a clinical-stage biotech, Forte Biosciences has not yet commercialized any products and is dependent on advancing its pipeline through clinical trials. Monoclonal antibody therapeutics are a well-established modality in the biotechnology sector, commonly used to target specific immune system proteins in autoimmune and inflammatory diseases.
- FB-102 Phase 1 celiac disease data readout expected
- Pipeline expansion into vitiligo and alopecia areata indications
- Cash runway critical as clinical-stage burn continues
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.88 > 0.02 and ΔFCF/TA -15.60 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.88 > 3% & CFO -59.3m > Net Income -75.9m |
| Net Debt/EBITDA: error (cannot be calculated) |
| Current Ratio: 2.75 > 1.5 & < 3 |
| Outstanding Shares: last quarter (178.4m) vs 12m ago 1.46k% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.08%; Δ -0.08% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.62 (Total Current Assets 65.1m - Total Current Liabilities 23.6m) / Total Assets 67.2m |
| B: -3.65 (Retained Earnings -245.5m / Total Assets 67.2m) |
| C: -1.30 (EBIT TTM -74.4m / Avg Total Assets 57.3m) |
| D: 1.68 (Book Value of Equity 42.1m / Total Liabilities 25.1m) |
| Altman-Z'' = -14.82 = D |
As of July 08, 2026, the stock is trading at USD 22.25 with a total of 500,696 shares traded. Over the past week, the price has changed by +4.36%, over one month by +41.99%, over three months by -14.98% and over the past year by +75.89%.
Current recommended Stop Loss: 20.20 (which is 9.2% or 1.3 ATR below the current price).
Forte Biosciences has received a consensus analysts rating of 5.00. Therefore, it is recommended to buy FBRX.
- StrongBuy: 4
- Buy: 0
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 63.8 | 186.5% |
P/B = 10.3707
Revenue TTM = 0.0 USD
EBIT TTM = -74.4m USD
EBITDA TTM = -74.4m USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 370.2m USD (428.4m + (null Debt) - CCE 58.2m)
Interest Coverage Ratio = unknown (Ebit TTM -74.4m / Interest Expense TTM 0.0)
EV/FCF = -6.23x (Enterprise Value 370.2m / FCF TTM -59.4m)
FCF Yield = -16.04% (FCF TTM -59.4m / Enterprise Value 370.2m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 6.00k) / Revenue TTM)
Tobins Q-Ratio = 5.51 (Enterprise Value 370.2m / Total Assets 67.2m)
Interest Expense / Debt = unknown (Interest Expense 0.0 / Debt none)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -58.8m (EBIT -74.4m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.75 (Total Current Assets 65.1m / Total Current Liabilities 23.6m)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA -74.4m)
Debt / FCF = unknown (Net Debt none / FCF TTM -59.4m)
Total Stockholder Equity = 71.5m (last 4 quarters mean from totalStockholderEquity)
RoA = -132.3% (out of range, set to none)
RoE = -106.2% (Net Income TTM -75.9m / Total Stockholder Equity 71.5m)
RoCE = -170.8% (out of range, set to none) (EBIT -74.4m / Capital Employed (Total Assets 67.2m - Current Liab 23.6m))
RoIC = -135.0% (out of range, set to none) (NOPAT -58.8m / Invested Capital 43.6m)
WACC = 9.25% (E(428.4m)/V(428.4m) * Re(9.25%) + (debt-free company))
Discount Rate = 9.25% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 68.89 | Cagr: 102.8%
[DCF] Fair Price = unknown (Cash Flow -59.4m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.07 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.0 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-1.01 | Chg30d=+4.05% | Revisions=+0% | Analysts=4
EPS next Quarter (2026-09-30): EPS=-1.00 | Chg30d=+3.37% | Revisions=+29% | Analysts=4
EPS current Year (2026-12-31): EPS=-4.01 | Chg30d=+0.00% | Revisions=+38% | GrowthEPS=+14.9% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-4.14 | Chg30d=+0.00% | Revisions=+12% | GrowthEPS=-3.3% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: +29% (up=12, down=6)